Analyst Maintains Outperform Rating
This is a news story, published by Yahoo Finance, that relates primarily to Sami Corwin news.
Sami Corwin news
For more Sami Corwin news, you can click here:
more Sami Corwin newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsYahoo Finance news
For more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
gene therapy medicine RP. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest C3 inhibitor news, thrombotic microangiopathy news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
clinical holdInsider Trading & Hedge Fund Data, and Investment Newsletter From Insider Monkey
•Health
Health
William Blair Reaffirms Outperform Rating on Rocket Pharma Despite Trial Setback

76% Informative
Sami Corwin maintained his Outperform rating on Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) on May 27 with no price target, despite the company's recent difficulties.
The biotechnology company's trial for the gene therapy medicine RP-A501 was clinically halted and a patient tragically passed away.
RCKT stock's price tanking by around 80% year-to-date .
VR Score
74
Informative language
74
Neutral language
0
Article tone
formal
Language
English
Language complexity
60
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
3
Source diversity
1
Affiliate links
no affiliate links